Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04751760
Status:
RECRUITING
Last Update Posted:
2024-03-29
First Post:
2021-02-08
Brief Title:
Feasibility Study of a New Immunoglobulin E IgE Assay Method
Sponsor:
University Hospital Toulouse
Organization:
University Hospital Toulouse
Study Overview
Official Title:
Feasibility Study of a New Immunoglobulin E IgE Assay Method in Urine and Blood
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LuLISA
Brief Summary:
The main objective is to study the feasibility of a new specific IgE assay using a bioluminescence technique in a pediatric and adult allergic population For this we will collect blood and urine during a blood test scheduled for the follow-up of the patient
Detailed Description:
Allergy is a raising public health problem Specific IgE assays are useful tools to investigate the physiopathology of allergies This method is achieved mainly by the ImmunoCAP enzyme immunoassay technique This is an expensive test that requires a significant amount of blood This is a limitation particularly in children The time to get the results is long and a second consultation has to be scheduled in order to communicate the results to the patients The main objective of this study is to assess the feasibility of a new specific IgE assay named LuLISA using a bioluminescence technique in urine and blood samples from pediatric and adult allergic population This technique was recently published for the quantification of IgE against two peanut allergens and needs to be extended for the detection of other major allergens A secondary objective is the evaluation of the time needed to obtain results
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None